Acute Lymphoblastic Leukemia | Current Treatment: Physician Insights | US | 2022
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line treatment of B-cell ALL; however, the treatment paradigm has been transformed over the past two decades with the advent of targeted agents such as tyrosine kinase inhibitors (Novartis’s Gleevec, Bristol Myers Squibb’s Sprycel, and Takeda’s Iclusig). Bispecific T-cell engagers (Amgen’s Blincyto), antibody-drug conjugates (Pfizer’s Besponsa), and CAR T-cell therapies (Novartis’s Kymriah, Gilead’s Tecartus) have further diversified treatment options for relapsed or refractory (R/R) disease. The emergence of these targeted therapies has improved the prognosis for patients and continues to expand the ALL treatment armamentarium.
Questions answered
- What are the patient shares of key therapies and regimens used for pediatric, young adult, and adult ALL patients?
- What is the uptake of CAR T-cell therapies (Kymriah and Tecartus) in younger and older R/R ALL patient populations?
- How do drug-treatment rates vary across key ALL patient populations and by line of therapy?
- What are the key drivers and obstacles determining current prescribing patterns in ALL?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 100 U.S. hematologist-oncologists.
Key drugs covered: Kymriah, Tecartus, Blincyto, Besponsa, Gleevec, Sprycel, Iclusig, and Marqibo.
